Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.

Austrian Registry of Hypomethylating Agents EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) acute myeloid leukaemia azacitidine chronic myelomonocytic leukaemia health-related quality of life (HRQoL) mixed-effects linear models myelodysplastic syndromes patient-reported outcome (PRO) prognosis

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
22 Feb 2023
Historique:
received: 24 01 2023
revised: 10 02 2023
accepted: 17 02 2023
entrez: 11 3 2023
pubmed: 12 3 2023
medline: 12 3 2023
Statut: epublish

Résumé

In this prospective study (NCT01595295), 272 patients treated with azacitidine completed 1456 EuroQol 5-Dimension (EQ-5D) questionnaires. Linear mixed-effect modelling was used to incorporate longitudinal data. When compared with a matched reference population, myeloid patients reported more pronounced restrictions in usual activities (+28%,

Identifiants

pubmed: 36900181
pii: cancers15051388
doi: 10.3390/cancers15051388
pmc: PMC10000211
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
J Clin Oncol. 2002 May 15;20(10):2429-40
pubmed: 12011120
Eur J Haematol. 2014 Sep;93(3):198-206
pubmed: 24673368
Hematology. 2021 Dec;26(1):556-564
pubmed: 34384334
Value Health. 2019 Mar;22(3):355-361
pubmed: 30832974
Gesundheitswesen. 2005 Mar;67(3):173-82
pubmed: 15789280
Eur J Health Econ. 2013 Jul;14 Suppl 1:S1-3
pubmed: 23900659
Lancet Oncol. 2020 Nov;21(11):1513-1525
pubmed: 32926841
Cancers (Basel). 2022 May 17;14(10):
pubmed: 35626063
Cancer. 2018 Mar 15;124(6):1251-1259
pubmed: 29231969
Haematologica. 2020 Mar;105(3):632-639
pubmed: 31171638
Eur J Health Econ. 2019 Aug;20(6):933-944
pubmed: 31030292
Blood. 2006 Jul 15;108(2):419-25
pubmed: 16609072
Value Health. 2020 Jul;23(7):936-944
pubmed: 32762996
Sao Paulo Med J. 2007 Nov 1;125(6):359-61
pubmed: 18317610
Blood. 2013 Oct 24;122(17):2943-64
pubmed: 23980065
Qual Life Res. 2021 Mar;30(3):855-866
pubmed: 32965633
Exp Hematol. 2018 Sep;65:34-37
pubmed: 29883686
Future Oncol. 2019 Jun;15(16):1895-1909
pubmed: 30912462
Int J Environ Res Public Health. 2017 Apr 16;14(4):
pubmed: 28420153
Lancet Haematol. 2020 Dec;7(12):e874-e883
pubmed: 33242444
Lancet Haematol. 2021 Feb;8(2):e135-e148
pubmed: 33513373
Int J Mol Sci. 2017 Feb 15;18(2):
pubmed: 28212292
Qual Life Res. 2014 Mar;23(2):443-7
pubmed: 23921597
Am J Hematol. 2012 Nov;87(11):1006-9
pubmed: 23090887
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
Value Health. 2016 Sep - Oct;19(6):834-843
pubmed: 27712712
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
J Clin Oncol. 2020 Dec 10;38(35):4163-4174
pubmed: 33030979
Leukemia. 2020 May;34(5):1394-1406
pubmed: 31811236
BMJ Support Palliat Care. 2016 Mar;6(1):80-8
pubmed: 25204541
Eur J Health Econ. 2019 Jun;20(Suppl 1):119-132
pubmed: 31104218
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Am J Blood Res. 2012;2(2):136-47
pubmed: 22762033
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Pharmacoeconomics. 2018 Jun;36(6):663-674
pubmed: 29460066
Bone Marrow Transplant. 2015 Sep;50(9):1241-9
pubmed: 26076127
Lancet Oncol. 2015 Nov;16(15):1506-1514
pubmed: 26404501
Value Health. 2008 Mar-Apr;11(2):275-84
pubmed: 18380640
Health Qual Life Outcomes. 2007 Dec 21;5:70
pubmed: 18154669
Br J Haematol. 1998 Mar;100(4):629-36
pubmed: 9531327
Value Health. 2014 Jun;17(4):445-53
pubmed: 24969006
Blood Cancer J. 2022 Apr 20;12(4):71
pubmed: 35443742
Oncol Ther. 2019 Jun;7(1):67-81
pubmed: 32700197
Psychother Psychosom Med Psychol. 2006 Feb;56(2):42-8
pubmed: 16453241
Blood Adv. 2020 May 26;4(10):2339-2350
pubmed: 32453839
Leukemia. 2018 Jun;32(6):1380-1392
pubmed: 29572506
Eur J Health Econ. 2005 Jun;6(2):124-30
pubmed: 19787848
Leuk Lymphoma. 2019 Jul;60(7):1721-1730
pubmed: 30424699
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730
BMC Res Notes. 2019 Jan 14;12(1):18
pubmed: 30642397
Cancer. 2020 Aug 1;126(15):3542-3551
pubmed: 32463931
Med Care. 2007 Sep;45(9):812-9
pubmed: 17712251
Health Qual Life Outcomes. 2009 Sep 08;7:81
pubmed: 19737399

Auteurs

Lisa Pleyer (L)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria.
3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, Austria.

Sonja Heibl (S)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
4th Medical Department of Internal Medicine, Hematology, Internistic Oncology and Palliative Medicine, Klinikum Wels-Grieskirchen GmbH, 4600 Wels, Austria.

Christoph Tinchon (C)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Department for Hemato-Oncology, LKH Hochsteiermark, 8700 Leoben, Austria.

Sonia Vallet (S)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Department of Internal Medicine 2, University Hospital Krems, Karl Landsteiner Private University of Health Sciences, 3500 Krems, Austria.

Martin Schreder (M)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
1st Department of Internal Medicine, Center for Oncology and Hematology, Klinik Ottakring, Wiener Gesundheitsverbund, 1030 Vienna, Austria.

Thomas Melchardt (T)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria.
3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, Austria.

Norbert Stute (N)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria.
3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, Austria.

Kim Tamara Föhrenbach Quiroz (KT)

Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria.

Michael Leisch (M)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria.
3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, Austria.

Alexander Egle (A)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria.
3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, Austria.

Lukas Scagnetti (L)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
4th Medical Department of Internal Medicine, Hematology, Internistic Oncology and Palliative Medicine, Klinikum Wels-Grieskirchen GmbH, 4600 Wels, Austria.

Dominik Wolf (D)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Department of Internal Medicine V, Innsbruck Medical University, 6020 Innsbruck, Austria.

Richard Beswick (R)

International Marketing, Swiss Business School, 8302 Zurich, Switzerland.

Manuel Drost (M)

Assign Data Management and Biostatistics GmbH, 6020 Innsbruck, Austria.

Julian Larcher-Senn (J)

Assign Data Management and Biostatistics GmbH, 6020 Innsbruck, Austria.

Thomas Grochtdreis (T)

Department of Health Economics and Health Services Research, Hamburg Center for Health Economics, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.

Marc Vaisband (M)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria.
Life and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany.

Jan Hasenauer (J)

Life and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany.

Nadja Zaborsky (N)

Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria.
3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, Austria.
Laboratory of Immunological and Molecular Cancer Research (LIMCR), 5020 Salzburg, Austria.

Richard Greil (R)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria.
3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, Austria.

Reinhard Stauder (R)

Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Department of Internal Medicine V, Innsbruck Medical University, 6020 Innsbruck, Austria.

Classifications MeSH